Oct. 7 at 4:44 PM
$SPRB $ZNB $KRMA keep this under your radar
$NCNA Catalysts β
Compliance with all Nasdaq Continued Listing Criteria Strong Cash Runway into 2029.β
Recent RS sub 2M floater with tight shares structure right now β
Data π this week β
Trading below cash and potential multi Bullion MC in the cancer market β
Early NUC-7738 results: 27 patients across multiple cancers.
The drug lasted in the body long enough for weekly dosing.
Safety was strong. No life-threatening side effects, and only occasional serious fatigue or anemia.
Even in heavily pre-treated patients, doctors saw tumor shrinkage: 14β46% reductions in individual cases, and a 41% overall disease control rate.
For a first-in-human study, those are promising signals.β
DATA coming soon β